Infographics - Recombinant Vaccine Market

Recombinant vaccines are products of genetic engineering, in which a harmless agent, such as yeast, is programmed to produce antigens of diseases. A small piece of DNA is extracted from the virus or bacteria against which protection is required and inserted into the manufacturing cells. To manufacture the hepatitis B vaccine, for example, a part of the hepatitis B virus's DNA is inserted into the DNA of yeast cells. These yeast cells can then manufacture one of the hepatitis B virus's surface proteins, which is purified and used as the active ingredient in the vaccine. The benefit of recombinant vaccines is that they can also be utilized for patients with compromised immune systems. These vaccines are safe and have less or no side-effects as compared to conventional vaccines, in the prevention of various diseases such as influenza, cholera, typhoid, and dengue. Recombinant vaccines are also used in animals for prevention of diseases such as foot and mouth disease, pneumonia and septicemia, and pox disease. Vaccination results in the prevention of disease, by producing antibodies against the protein antigen of pathogenic microorganisms.

Market Dynamics

Increasing approvals by regulatory bodies to key players for recombinant vaccines is expected to drive market growth over the forecast period. For instance, in December 2021, Serum Institute of India Pvt. Ltd., a vaccine manufacturer, and Novavax, a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, received emergency use authorization (EUA) for Novavax's recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M adjuvant by the Drugs Controller General of India (DCGI).

Key features of the study:

This report provides in-depth analysis of the global recombinant vaccines market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global recombinant vaccines market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, GSK plc., GC Biopharma, Bayer AG, Bharat Biotech, Serum Institute of India Pvt. Ltd., Sartorius AG, Johnson & Johnson Services, Inc., and Bio Farma
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global recombinant vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global recombinant vaccines market

Detailed Segmentation:

Global Recombinant Vaccines Market, By Product Type:
- Subunit Recombinant Vaccines
- Attenuated Recombinant Vaccines
- Vector Recombinant Vaccines
Global Recombinant Vaccines Market, By Disease Type:
- Infectious Disease
- Cancer
- Allergy
- Others
Global Recombinant Vaccines Market, By End User:
- Recombinant Human Vaccines
- Animal Recombinant Vaccines Hospitals
  - Poultry
  - Companion Animal Vaccines
  - Livestock
  - Porcine
  - Aquaculture Vaccines
Global Recombinant Vaccines Market, By Region:
- North America
  - By Country
    - U.S.
    - Canada
- Latin America
  - By Country
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - By Country
    - Germany
    - U.K.
    - France
    - Italy
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - By Country
    - China
    - India
    - Japan
    - Australia
    - South Korea
    - ASEAN
    - Rest of Asia Pacific
- Middle East
  - By Country
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - By Region/Country
    - South Africa
    - Central Africa
    - North Africa
Company Profiles
- Merck & Co., Inc.
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Novartis AG
- Pfizer Inc.
- Sanofi
- GSK plc.
- GC Biopharma
- Bayer AG
- Bharat Biotech
- Serum Institute of India Pvt. Ltd.
- Sartorius AG
- Johnson & Johnson Services, Inc.
- Bio Farma

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
Market Purview
- Report Description
  - Market Definition and Scope
- Executive Summary
  - Market Snapshot, By Product Type
  - Market Snapshot, By Disease Type
  - Market Snapshota, By End User
  - Market Snapshot, By Region
- Coherent Opportunity Map (COM)
Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
  - Drivers
  - Restraints
  - Market Opportunities
- Impact Analysis
- Market Trends
- Recent Developments
- Acquisitions and Partnerships Scenario
- Technology Overview
- Regulatory Scenario
- Pricing Analysis
- PEST Analysis
Global Recombinant Vaccines Market- Impact of Coronavirus (Covid-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the market
Global Recombinant Vaccines Market, By Product Type, 2017 – 2030, (US$ Million)
- Overview
  - Market Share Analysis, 2022 and 2030 (%)
  - Y-o-Y Growth Analysis, 2018 – 2030
  - Segment Trends
- Subunit Recombinant Vaccines
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Attenuated Recombinant Vaccines
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Vector Recombinant Vaccines
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
Global Recombinant Vaccines Market, By Disease Type, 2017 – 2030, (US$ Million)
- Overview
  - Market Share Analysis, 2022 and 2030 (%)
  - Y-o-Y Growth Analysis, 2018 – 2030
  - Segment Trends
- Infectious Disease
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Cancer
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Allergy
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Others
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
Global Recombinant Vaccines Market, By End User, 2017 – 2030, (US$ Million)
- Overview
  - Market Share Analysis, 2022 and 2030 (%)
  - Y-o-Y Growth Analysis, 2018 – 2030
  - Segment Trends
- Recombinant Human Vaccines
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Animal Recombinant Vaccines
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    - Poultry
    - Companion Animal Vaccines
    - Livestock
    - Porcine
    - Aquaculture Vaccines
Global Recombinant Vaccines Market, By Region, 2017 – 2030, (US$ Million)
- Introduction
  - Market Share Analysis, By Region, 2022 and 2030 (%)
  - Y-o-Y Growth Analysis, For Regions, 2018–2030
  - Regional Trends
- North America
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
    - U.S.
    - Canada
- Latin America
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
    - UK
    - Germany
    - Italy
    - France
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
    - China
    - India
    - Japan
    - ASEAN
    - Australia
    - South Korea
    - Rest of Asia Pacific
- Middle East
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 – 2030, (US$ Million)
    - North Africa
    - Central Africa
    - South Africa
Competitive Landscape
- Merck & Co., Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Novartis AG
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Pfizer Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Sanofi
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- GSK plc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- GC Biopharma
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Bayer AG
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Bharat Biotech
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Serum Institute of India Pvt. Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Sartorius AG
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Johnson & Johnson Services, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Bio Farma
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
Section
- Research Methodology
- About Us

*Browse 27 market data tables and 31 figures on "Recombinant Vcacines Market” - Global forecast to 2030

View Our Licence Options

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now

Credibility and Certifications

860519526

9001:2015

27001:2022

RECOMBINANT VACCINE MARKET ANALYSIS

Recombinant Vaccine Market

Need a Custom Report?

EXISTING CLIENTELE